To receive information from ONCODESIGN PRECISION MEDICINE (OPM) in real time, send a request to [email protected]
Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Ticker: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancers (the “Company”), announces the result of its capital increase with priority deadline for shareholders for an amount of approximately €2 million.
The capital increase, for a total gross amount of approximately €2.0 million, share premium included, will result in the issue of 1,511,364 New Shares.